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Abstract 
In recent years, breast cancer has been the most common cancer and the most common 
cause of disability among women in developed countries. 
Determining the role of the quality of life parameter of patients during complex 
neoadjuvant treatment with the use of polychemotherapy in systemic (SPCT), endolymphatic 
(ELPCT) and selective intraarterial (SIAPCT) variants in patients with locally advanced 
breast cancer M. 
The study was conducted on the basis of materials from 526 cases of MR RMZ T4A-
DN0-2M0. The total sample was divided into three subgroups by parameter of route of 
neoadjuvant polychemotherapy (PCT): first control group (22 patients) - SPCT; the second 
control group (27 patients) - ELPCT; study group (41 patients) - SIAPCT. 
Clinical effect with qualitative changes of local status and transfer of patients to the 
category of those with resectable tumors appeared in 46% of women of the first control group 
after 6 courses of SPCT, in 59% of the second control group after 4 courses of ELPHT and in 
90% of the studied group after 3 courses SIAPCT. 
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After 3 courses of PCT, statistically better results of the experimental group were 
obtained in the positive dynamics of quality of life index in the amplitude and chronometric 
complex logran study as a result of neoadjuvant SIAPCT compared with the first (p<0.001) 
and second (p<0.05) control groups. 
On the social well-being scale, the control group showed the best dynamics (p> 0.05 in 
both comparisons) with a high evaluation of restitution of work and social status. 
On the symptom scales in the third group, after each course of polychemotherapy, 
symptoms of nausea and loss of appetite were observed at a significantly lower intensity 
compared to both control groups within 15 - 25 points of the group (p<0.05 in both 
comparisons) and lasted 1 - 2 days less ( p<0.05 in both comparisons). 
Quality of life (QOL) research is a reliable, informative, and cost-effective method for 
assessing a patient's state of health at both group and individual levels. In cancer studies, QOL 
assessment is an important criterion for evaluating treatment effectiveness and is of 
prognostic value. 
Key words: locally advanced breast cancer; systemic polychemotherapy; 
endolymphatic polychemotherapy; selective intra-arterial polychemotherapy; quality of 
life. 
 
Introduction. Breast cancer (BC) is the most common cancer among women 
worldwide [1]. This is partly due to the increase in the number of breast cancer patients [2]. 
Statistics show that every year more than one million women worldwide find out about their 
diagnosis for the first time and more than half a million die from the disease [3]. On the other 
hand, individualized and specialized programs for complex treatment of breast cancer have 
led to an increase in the survival rate of these patients [4]. 
Diagnosis and living with BC is a very stressful experience that can adversely affect 
many aspects of human life and health and can have a long-term effect after treatment [5]. 
Along with an increase in the number of patients with breast cancer and an increase in 
survival due to advances in medical technology, accurate assessment of their quality of life 
(QOL) is crucial [6]. 
In addition to health, breast cancer affects the identity of women, and therefore the 
study of the quality of life of women with the disease is fundamentally important in the 
context of comprehensive examination to reproduce the full understanding of the problem on 
behalf of the patient, as well as to formulate tactics for complex treatment of physical, mental, 
social and cognitive disorders caused by disease and therapy [7, 8]. For this reason, quality of 
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life has become a common criterion for evaluating outcomes for cancer patients and an 
integral part of their management. By far, one of the most popular QOL oncology tools is the 
EORTC-C30-QLQ-C30 European Quality of Life Questionnaire [9, 10]. 
To answer the question to what extent the study of the quality of life of patients with 
breast cancer has altered our understanding or contributed to the improvement of the results of 
breast cancer treatment - it is necessary to study the relationship of subjective and objective 
treatment indices in dynamics in each specific research. 
The aim of our study. Determination of the role of the quality of life parameter of 
patients during complex neoadjuvant treatment using polychemotherapy in systemic (SPCT), 
endolymphatic (ELPCT) and selective intraarterial (SIAPCT) variants in patients with locally 
advanced breast canceer (LABC). 
Materials and methods 
After standardization by target age and clinical parameters, the total sample was 
divided into three subgroups by the parameter of polychemotherapy (PCT) administration, 
which was used in the complex neoadjuvant treatment: first control group (89 patients) - 
systemic PCT; second control group (75 patients) - endolymphatic PCT; study group (362 
patients) - selective intra-arterial PCT. 
The study of patients' quality of life was conducted within the framework of the 
International Protocol of the European Organization for Research and Treatment of Cancer 
using the European Organization for the Research and Treatment of Cancer (EORTC QLQ-
C30) questionnaire. Patients were interviewed within 1 week before PCT onset and 10-14 
days after PCT. 
At all stages of the statistical analysis, standard features of MS Excel were used to 
prepare the primary spreadsheets and group the features. The mean, (M), standard error (m), 
and median were calculated to to evaluate the quantitative indicators. Pearson's χ2 criterion 
was used to compare non-parametric indicators, and Mann-Whitney test was used for 
parametric values. To estimate the incremental changes in nonparametric indices within one 
group, the Mc-Nemar χ2 criterion was used, and the Wilcoxon test was used for parametric 
values. In all cases, the differences were considered statistically significant at a significance 
level of p<0.05. 
Results  
The general condition of patients at all stages is formed mainly due to the objective 
(presence of tumor neoplasm; intoxication syndrome; asthenic syndrome; local and systemic 
manifestations of tumor lysis; attachment of secondary infection of compromised tissues) and 
  377 
subjective (psychological and emotional state, social maladaptation through cancer stigma 
and disability) factors. After QOL index analysis (Fig. 1) there were no statistically 
significant differences found according to Kolmogorov-Smirnov estimation: in the 
experimental group the average value was 53.0±7.4 points, in the first control – 54.0±8.2 
points, in the second control – 56.0±4.1 points. 
 
  
 
Fig. 1. Quality of life (QOL) of patients before and after neoadjuvant 
polychemotherapy 
 
After completion of the 1st course of chemotherapy, the QOL indicator had a negative 
trend in the first (decrease by 7% with a final result of 47±4.3 points), in the second (decrease 
by 5% with a final result of 51±3.1 points) and the third (decrease by 6% with a final result of 
47±5.6 points) groups, maintaining proportional statistical discrepancy in results. Such 
dynamics of indicators are connected, first of all, with the advent of toxic effects of 
chemotherapy treatment, of which most patients were negatively informed by the media. On 
the other hand, there was also an insufficient level of compliance with patients and an 
insufficient explanation of the essence of treatment: persistence of intoxication syndrome, 
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dissonance of expected and actual changes in tumor dimensions, panic fear of failure of 
treatment and lack of well-being improvement was interpreted by some patients as a negative 
result. 
In 32 patients of group 1, 22 - of the second and 94 - of the third there were signs of 
negative dynamics according to RECIST criteria, as a result of which they were transferred to 
systemic polychemotherapy with the use of drugs 2 and 3 lines. 
At the same time, patients of group 3 had the greatest discrepancy between the 
evaluation of QOL and the real dynamics of the local tumor status: in 268 persons there was a 
complete reduction of the signs of tissue disintegration and secondary infection in all persons 
with ulcerative-destructive forms of LABC; there was no re-regression of the wound after 
debridement. In the majority of patients of groups 1 (57 persons) and 2 (53 persons) with 
superficial destructive forms of LABC similar effect had temporary character (on average, 
within 2 weeks) - with the phenomena of partial recurrence of ulceration on the surface of the 
affected skin, although of much less intensity. However, the stabilization of the process was 
not perceived by the patients as a positive result, and systemic manifestations of intoxication 
were prevalent. 
After the second course of PCT, there was a further decrease of the index in the first 
(by 4% to 43±4.3 points) and the second (by 6% to 45±3.1 points) control groups, with an 
acute increase in the parameter value in the experimental group (increase by 12% with a final 
result of 59±4.9 points). The difference between the results was statistically significant in the 
comparison between the experimental and the two control groups (p<0.05 for the pair [groups 
1 and 3], and p<0.05 for the pair [groups 2 and 3]). 
After the completion of the third course of chemotherapy, the reference values of QOL 
parameter were positive in all groups: QOL increase was noted in patients of group 1 (7% to 
52±2.3 points) and 2 groups (9% to 54±6.8 points) as a result of improvement of the general 
condition, addiction to systematic wave-like dynamics of PCT intoxication symptoms, 
positive dynamics of local tumor status. Three courses of PCT were sufficient for 261 patients 
in the study group, after which they completed a non-adjuvant chemotherapy course and 
began receiving further treatment. This is reflected in the QOL score of this cohort: further 
significant improvement in quality of life by 18 points with a final result of 77±6.3 points. 
The statistical advantage remained significant with p<0.001. 
A further study of quality of life was conducted in degenerative form, given the lack of 
data from group 3; at this stage, 261 patients had positive clinical dynamics followed by 
radiotherapy and operative steps, and 101 patients had to change their neoadjuvant PCT 
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regimen due to negative dynamics or no effect of therapy. Fifty patients on systemic PCT and 
48 patients on endolymphatic showed moderate positive dynamics of RECIST regression with 
better results in the second group (p<0.05). 
After completing 4 courses of PCT, the scores decreased by one or two points in both 
control groups (51±4.4 and 52±2.3 points, respectively) and remained at the same level in 
patients of group 1 during subsequent cycles of NPCT, which was interpreted as a result of 
physical and moral exhaustion of patients. , absence of the same dynamics of clinical 
symptoms as in other patients, lack of positive results and dissatisfaction with the symptoms 
of iatrogenic intoxication. 
Clinical effect with qualitative changes of local status and transfer of patients to the 
category of resectable tumors appeared in 50 women of the first control group after 6 courses 
of SPCT, in 48 - the second control group after 4 courses of ELPCT and 261 patients of the 
experimental group. 
The presented data demonstrate statistically better results of the experimental group on 
the positive dynamics of the quality of life index in the amplitude and chronometric complex 
logran study as a result of neoadjuvant SIAPCT compared to the first (p<0.001) and second 
(p<0.05) control groups. According to the results of the general state scale, the following 
dynamics were observed: statistically unreliable difference when compared to the beginning 
of chemotherapy (63±6.4 points in the first group, 65±4.3 points in the second group, 59±3.8 
points in the third group; p> 0.05 in both pairs of comparisons) with a linear deterioration of 
5-10 points after the first 2 courses of PCT and a further improvement in the range of 10 
points in the third group without dynamics in the control groups. The following dynamics 
were observed in the evaluation of the physical health scale: statistically unreliable difference 
when compared to the beginning of chemotherapy (83±5.4 points in the first group 81±9.6 
points in the second group, 85±9.6 points in the third group, χ2>0.05 in both comparison 
groups) with statistically acceptable fluctuations in the range of 10 points in all groups during 
the period of neoadjuvant treatment. 
The cognitive status was the least responsive to chemotherapy: the intergroup and 
intragroup incomplete differentials were within the range of 10 points and had no statistical 
differences in all three groups. Indicators of emotional state and social well-being revealed the 
most variable pattern. And if, on the scale of the emotional state, changes occurred 
haphazardly (p>0.05 in both comparisons), which certainly makes this parameter the most 
subjective and the least reliable for a separate assessment, but, as already mentioned, 
necessary for a comprehensive approach; then the social adaptation scale reflects a bright 
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positive dynamic for the third group and more moderate for the first and second and is, in the 
authors' opinion, the most important parameter in the quality of life indicator. 
As already stated, improving social adaptation (both physically, through the ability to 
eliminate the potential source of tissue destruction, and morally - by eliminating the patient's 
stigmatization and giving them the opportunity to return to normal life) and restoring the 
health is the ultimate goal of comprehensive treatment and interim treatment. for each of the 
steps. 
Prior to chemotherapy, patients rated their social status equally low (47±3.7 points in 
the 1st group, 49±3.9 points in the 2nd group and 51±5.7 points in the 3rd). After the first two 
courses of PCT in both groups, the scores improved: 12 points in patients of the first control 
group, making 59±7.2 points, 14 points in patients of the second control group, making 
64±7.2 points, and 22 points in the experimental cohort of 69±8.9 points. 
In the future, positive dynamics persisted: in the first group, an increase of 19 points 
(68±7.1 points) after the third course and another 6 points (74±4.6 points) after the fourth; in 
the second - by 16 points (65±4.9 points) in the third stage of the study and by 6 points 
(72±6.3 points) in the fourth; in the third - by 16 points (80±5.3 points) in the third stage of 
the study. At the same time, objective reduction of local symptoms in all categories was really 
observed in patients with significant temporal and amplitude predominance of the third group. 
This dynamic of assessing one's social status is crucial in treating advanced forms of 
cancer, especially breast cancer, as a result of a positive change in a woman's perception of 
herself as a full member of society and her illness - not as a stigma that condemns death and 
deprives the struggle for survival of meaning, but as a condition in which there is medical 
care that allows to increase the length and quality of later life and to restore social and 
employment status (p>0.05 in both comparisons in favor of the control group). 
Finally, the symptomatic panel selected only those that had high reference values, 
statistical significance, and pathogenetic association with the intervention: pain, nausea, and 
loss of appetite - as parameters that characterize local and general changes in the body. 
Intoxication syndrome is a serious and major side effect of chemotherapy treatment. It 
should be noted that objectively, the symptoms of intoxication persisted for an average of 5-7 
days after systemic and endolymphatic administration of the drugs and 3-5 days after regional 
perfusion. 
Due to the rational selection of drugs for chemotherapy, intoxication did not reach a 
pronounced scale, so the parameters of insomnia, apathy, depression and general fatigue did 
not change significantly. 
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Symptoms of nausea and loss of appetite were noted in several patients with first-stage 
tumor lysis syndrome, which averages low (13±1.4 and 11±0.9, respectively, in the 1st group, 
13±1.2, and 11±0.7, respectively, in the 2nd group, 10±0.9 and 10±1.1 - in the 3rd group). In 
subsequent stages, loss of appetite and nausea was noted by almost all patients in both control 
groups as a response to iatrogenic chemotherapy aggression over typical time intervals and 
evaluated as severe. In the third group, after each course of polychemotherapy, symptoms of 
nausea and loss of appetite were markedly less intense compared to both control groups 
within 15-25 points of the group (p<0.05 in both comparisons) and lasted 1-2 days less 
(p<0.05 in both comparisons), which characterizes the better tolerability of selective intra-
arterial PCT due to a rational dosing system (⅓ the course dose of each drug per day) while 
maintaining efficacy due to the “shock effect” of regional perfusion. 
The pain syndrome and its dynamics during the period of neoadjuvant treatment 
require special characteristics. In general, it reflects the dynamics of the local process, and 
therefore correlates with the system of clinical effect (tumor resectability) and is almost 
indistinguishable between groups. 
Complaints and discomfort in the affected breast or in the tumor itself were noted by 
all patients of the first group in varying degrees of intensity in the form of actually pain 
syndrome in - the first (a) 65 (73%), the second (b) 56 (75%), the third (c) 235 (65%) groups 
of patients – or its equivalents: feeling of heaviness, compression, itching, paresthesia - a) 34 
(27%), b) 19 (25%), c) 127 (35%) of clinical cases. Prior to the onset of chemotherapy 
treatment, high intensity pain syndrome (requiring injection of non-steroidal analgesics for 24 
hours without complete reduction of discomfort) was characteristic of a) 4 (4%), b) 1 (1%), c) 
29 ( 8%) cases of coccross mastitis by type of inflammatory pain syndrome, medium intensity 
(satisfactory control of pain syndrome by oral NSAIDs with non-permanent use of injection 
forms - for a) 34 (38%), b) 29 (39%), c) 116 (32%) cases of invasion into the elements of the 
chest wall by type are not and (a) 27 (30%), b) 16 (21%), c) 90 (25%) cases of breast cancer 
with mixed type of pain syndrome. 
According to the linear visual-analogue scale (VAS), the mean pain intensity M±m 
was a) 17.5±8.8, b) 16.2±5.7, c) 18.0±6.3. In general, during the neoadjuvant PCT, the 
proportions and distribution of pain syndrome incidents and its equivalents were maintained, 
while their intensity varied widely, which had the following tendency: during the first course 
of PCT and during the first days after its completion, there was an increase in the intensity of 
existing symptoms ( a) +22, b) +16, c) +9 points) by increasing the cytotoxic effect of the 
synthesis of inflammatory mediators in damaged tissues with increased edema and hyperemia, 
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an increase in intra-tissue pressure, blood circulation and cell metabolism. Subsequent 
reduction to a) 14.2, b) 9.1, c) 1.9 points after the second PCT cycle and a) 2.2, b) 2.0, c) 1 
points after the third (when paired comparison of the study group with both control groups 
p>0.05) is explained by the effectiveness of the first effective PCT courses in reducing the 
tumor cell volume and reducing perifocal infiltration with a decrease in mediator synthesis 
activity and inhibition of the local inflammation process. 
The described dynamics indicate a higher efficiency of selective intra-arterial 
chemotherapy and antibiotic therapy in relation to the reduction of intensity (p<0.05) and 
duration (p>0.05) of the inflammation and pain syndrome during neoadjuvant treatment. 
The general condition of patients at all stages is formed mainly due to the objective 
(presence of tumor neoplasm; intoxication syndrome; asthenic syndrome; local and systemic 
manifestations of tumor lysis; attachment of secondary infection of compromised tissues) and 
subjective (psychological and emotional state). , social maladaptation through cancer stigma 
and disability) factors. 
After 3 courses of PCT, statistically better results of the experimental group were 
obtained by positive dynamics of the quality of life index in the amplitude and chronometric 
complex logran study as a result of neoadjuvant SIAPCT compared to the first (p<0.001) and 
second (p<0.05) control groups. 
The physical scale was strongly and directly correlated with objective changes in the 
breast after neoadjuvant treatment with significantly better results in group 3 (p<0.05). 
The lowest cognitive response rate (p>0.05 for all groups) responded to chemotherapy. 
The most variable pattern was found by indicators of emotional state (p> 0.05 for all groups). 
On the social well-being scale, the control group showed the best dynamics (p> 0.05 in both 
comparisons) with a high evaluation of restitution of work and social status. 
On the symptom scales in the third group, after each course of polychemotherapy, 
symptoms of nausea and loss of appetite were observed at a significantly lower intensity 
compared to both control groups within 15-25 points of the group (p<0.05 in both 
comparisons) and lasted 1-2 days less (p<0.05 in both comparisons). 
Conclusions  
1. The scheme of complex neoadjuvant treatment based on SIAPCT allowed to 
improve the overall tolerability and psycho-emotional background of patients during the 
period of polychemotherapy and to increase the overall quality of their life in the fields of 
mental and physical condition (p<0.05) compared to those receiving standard treatment. 
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2. The investigation of QOL is a reliable, informative, and cost-effective method of 
assessing a patient's health at both group and individual levels. In cancer studies, QOL 
assessment is an important criterion for evaluating treatment effectiveness and is of 
prognostic value. 
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